According to CNN, the American company "Pfizer" and the German "Biontech" announced today the final results of the Coronavirus vaccine clinical tests which reached 95%.
"Pfizer" and "Biontech" are planning to present their vaccine to obtain approval for emergency use before sharing it with other countries around the world.
The analysis of the final effectiveness of the vaccine was 95% within 28 days of the first dose, which is higher than what was announced last week for the third phase of clinical trials of the vaccine.
The vaccine achieved 94% effectiveness on the groups over 65 years old, and no serious safety concerns were reported.
The two companies announced Monday that the Covid-19 vaccine that they are developing is "90 per cent effective" after preliminary analysis of the results of the third phase of clinical trials.
The two companies said in a joint statement that the effectiveness of the vaccine was measured by comparing the number of participants who were infected with Coronavirus in the group that received the vaccine and the number of infected people in another group that received another vaccine, seven days after receiving the second dose and 28 days after receiving the first dose.
The vaccine creates nucleic acids that stimulate cells in the human body to produce proteins similar to the virus, and those proteins would trigger the human body's immune response against the Coronavirus.
"Pfizer" has an agreement to sell 100 million doses of its vaccine to the US government, with the option to purchase 500 million additional doses. The company is also in talks with other governments, including the European Union, about similar deals.
The testing protocol urges for a relatively quick analysis of data, but scientists, biologists and experts in clinical tests have warned of the dangers of granting a quick approval, and prefer to test the vaccine for a few additional months, to ensure its effectiveness and possible side effects.
Follow the latest news on Google News
